{"schema_version":"1.0","type":"article","title":"美股迎來史上最大 Biotech IPO","url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.md","lang":"zh-Hant","date":"2026-06-29","publish_at":"2026-06-29T05:50:47.700Z","updated_at":"2026-06-29","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。","key_points":[],"facts":[],"sections":["Parabilis 給市場上的一堂課","01｜Parabilis 到底在做什麼？不是小分子，也不是抗體，而是 Helicons","02｜Zolucatetide：直接挑戰 β-catenin，這是最硬的一塊骨頭","03｜Regeneron 合作，讓平台價值被產業驗證","04｜為什麼是 Parabilis？答案不是單一因素","05｜這是美股 Biotech IPO 回暖，但不是概念股回暖","06｜這件事對台灣生技的啟示","結語｜Parabilis 創紀錄 IPO，不是市場瘋了，而是資本重新尋找硬科技資產"],"references":[{"title":"[0]: Parabilis Medicines 官方網站與投資人關係資料，","source":"","date":"","url":"https://parabilismed.com/"},{"title":"[1]: Parabilis Medicines, \"Parabilis Medicines Announces Pricing of Upsized Initial Public Offering\", 2026-06-09,","source":"","date":"","url":"https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-pricing-upsized-initial-public"},{"title":"[2]: Parabilis Medicines, \"Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares\", 2026-06-11,","source":"","date":"","url":"https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-closing-upsized-initial-public"},{"title":"[3]: Parabilis Medicines, \"About Helicons\",","source":"","date":"","url":"https://parabilismed.com/innovation/about-helicons/"},{"title":"[4]: Parabilis Medicines, \"Zolucatetide\",","source":"","date":"","url":"https://parabilismed.com/program/fog-001/"},{"title":"[5]: Parabilis Medicines, \"Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas\", 2026-05-18,","source":"","date":"","url":"https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-strategic-collaboration-regeneron"},{"title":"[6]: Parabilis Medicines, \"Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform\", 2026-01-08,","source":"","date":"","url":"https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-oversubscribed-305-million"}],"images":[{"alt":"Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 1）","url":"https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-01.png"},{"alt":"Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 2）","url":"https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-02.png"},{"alt":"Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 3）","url":"https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-03.png"},{"alt":"Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 4）","url":"https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-ipo/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-29）。美股迎來史上最大 Biotech IPO。https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-29-biotech-ipo-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}